Crossmark

Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial

Crossref DOI link: https://doi.org/10.1186/s12885-025-13826-5

Published Online: 2025-03-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Huang, Haichao

Wang, Tao

Li, Wei

Wu, Zhun

Wang, Xuegang

Xing, Jinchun

Chen, Bin

Zhang, Kaiyan
Funding

Funding for this research was provided by:

National Science Foundation of Fujian Province for Young Scientists (2020J05304)
License Information

Text and Data Mining valid from 2025-03-10

Version of Record valid from 2025-03-10
More Information

Article History

Received: 11 June 2024

Accepted: 27 February 2025

First Online: 10 March 2025

Declarations

:

: This study has been approved by the institutional ethics committee of the First Affiliated Hospital of Xiamen University. Written informed consent to participate will be obtained from all study participants.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below